1. Q1 23 Revenues 88.4 Cr vs Q1 22 106.8 Cr - Decline of 17%
2. EBITDA 15.2 Cr Q1 23 vs 26.3 Cr - Decline of 42%
3. EBITDA margins 17% for Q1 23 vs 25%
Forex loss of 4.9 Cr.
Actual EBITDA = 20.17 Cr. EBITDA margins 23%
4. Geopolitical issues, covid lockdowns in china and semiconductor shortages affected the company’s performance as SDAs demand gone down.
Expecting Good revival from Q3 FY 23 for SDA
5. SDA have highest margins compared the other products manufactured by Tatva Chintan
6. Electrolyte salt segment posted revenues of 6.9 cr for Q1 FY 23 vs 5.7 cr full year FY 22.
Application of zinc ion and sodium ion batteries is increasing.
7. Received the formal approval from the customer for energy storage application and manufacturing started.
Working with 2 more customers for the electrolyte salts segment.
8. Mono-glyme : Pilot stage equipment using continuous flow chemistry will be installed in Q2 23.
9. Another product pilot equipment is already set up & trials are going on.Commercial supply will take 15-18 months
10. New product in application of metal extraction has been formally approved by the customer and commercial supply will start from Q4 FY 23
Revenue potential : 30 to 40 Cr
11. Customers are not buying SDAs because of drop in demand & inventories are high.
From Q4 23 demand will normalize for SDAs. Maximum 10% drop of SDAs for full year of FY 23.
New Application of SDA based Zeolite catalyst is into recycling of waste.
Tatva Chintan developed the SDA for this application.
Since tatva chintan is not able to sell SDAs they are manufacturing more PTCs and selling them in the market. Added MNC customer from Europe and captured 80% of their volume.
12. Flame retardants : Successfully completed pilot plant trials. Necessary infra installed at plant scale & full scale production to begin from this week
Global market size of flame retardants is 150000 MT while tatva chintan is planning to set up the plant of 5000 MT.
There is no competitor for flame retardants in India. Global competitors are Lanxess, ICL, Albemarle
Capex Update :
There was a strike for construction material in Gujarat for 3 weeks, despite that it is expected to start the plant according to schedule in Q3 FY 23.
Adding 200 KL capacity, doubling the existing capacity. Revenues are expected to double after addition of new capex.
Register for model portfolio to watch more detailed analysis on various chemical and pharma businesses
#Syngene announced a 10 year agreement with Zoetis to manufacture the biological entity for Librela(bedinvetmab). It is the first monoclonal antibody for the treatment of osteoarthritis in dogs
1. About the drug
Currently, the product is only approved for sale in Europe but management has indicated that US approval is expected by the end of 2022. Zoetis launched the product in the second quarter of 2021 in Europe.
Sales for the product were $15 million in both Q3 and Q4 of 2021 and $20 million in Q1 of 2022. Zoetis management has said that the product will be a blockbuster by the end of 2022 bringing in $100 million from the EU alone. (Blockbuster product in animal health is products with
While both CROs and CDMOs work on novel drugs and help innovators reduce costs and time to market, there are some key differences between their business models.
1.Type of services provided
Contract Research Organizations (CRO) provide research services and clinical development support to innovative pharma companies to innovative pharma companies in the preclinical and clinical development stages of the drug development process.
They are usually not involved in the commercial manufacturing of the drug.
Contract Development and Manufacturing Organizations (CDMO) provide drug development, scale up and commercial manufacturing services to innovators.
1. They were able to add 100+ new clients during the year while increasing repeat business from existing clients
2. SynVent - their integrated drug discovery platform made good progress during the year. It is proving to be a particularly attractive model for emerging biotech companies which choose not to establish their own infrastructure.
3. Capex for the year was ₹621 Cr. 70% of it was spent on Discovery Services and Dedicated Centers, 10% was spent on Development Services and another 10% was spent on Manufacturing Services. The remaining investments were in
Suven Pharma is a Contract Development and Manufacturing Organization (CDMO). They support the global life sciences industry and fine chemical majors in their NCE development.
1. Introduction
• Natco pharma, is an India based pharmaceutical company involved in the manufacture and marketing of APIs and Finished Dosage Formulations.
• NATCO has established presence in the Domestic as well as International markets through its subsidiaries in markets like Brazil and Canada. .The US has the largest contribution out of their international business.
• On going chip shortage affected SDA revenues in Q4.
• SDA are used in manufacturing of zeolites which have application in emission control of vehicles.
• Q1 and Q2 will have lower demand due semiconductor shortage.
• Got formal approval from 2 large customers for SDA segment. Supply for one of the customer will start from Q2 2023, for second customer supply is expected to start from Jan 2023.